Performance Forecast - The company expects a net profit of 260 million to 300 million yuan for the current reporting period, compared to 238.09 million yuan in the same period last year, indicating a growth of 9.2% to 26% [1] - The expected net profit after deducting non-recurring gains is projected to be between 250 million and 280 million yuan, up from 218.55 million yuan year-on-year, reflecting a growth of 14.39% to 28.12% [1] - Basic earnings per share are anticipated to be between 0.15 yuan and 0.17 yuan, compared to 0.14 yuan per share in the previous year [1] Reasons for Performance Change - The company is following its "14th Five-Year" strategic plan, focusing on the core business of pharmaceutical sales while expanding into medical devices, reagents, traditional Chinese medicine health products, specialty pharmacies, emerging businesses, and third-party reserves [1] - Revenue growth is attributed to both organic development and external mergers and acquisitions, alongside improved network layout [1] - The company has strengthened cost control, resulting in a significant reduction in operating management expenses and financing costs [1]

Group 1 - The company held its 35th meeting of the 8th Supervisory Board on July 10, 2025, with all three supervisors present, and the meeting complied with relevant regulations [1][2] - The Supervisory Board approved the proposal to abolish the Supervisory Board and its members, transferring its powers to the Audit and Risk Committee of the Board of Directors [1][2] - The proposal to amend the company's articles of association was also approved, with details disclosed in a separate announcement [1][2] Group 2 - The company approved a proposal for share repurchase, with the details provided in a separate announcement [2]

Meeting Announcement - The company has announced the convening of the 2025 Third Extraordinary General Meeting of Shareholders on July 28, 2025, at 14:00 [1] - The meeting will include both on-site and online voting options for shareholders [1][2] Voting Procedures - Shareholders can vote either through the Shenzhen Stock Exchange trading system or the internet voting system, but must choose one method only [2][7] - Voting times for the online system are specified for July 28, 2025, with designated hours for both trading and internet voting [1][2] Eligibility and Attendance - All ordinary shareholders registered by the close of trading on July 23, 2025, are eligible to attend the meeting and vote [2] - The meeting will also be attended by company directors, supervisors, senior management, and appointed lawyers [2] Agenda Items - The meeting will discuss several proposals, including amendments to the "Rules of Procedure for Shareholders' Meetings" and "Rules of Procedure for Board Meetings," as well as details regarding share repurchase [5][11] - Certain proposals require a two-thirds majority of the voting rights held by attending shareholders to pass [5] Registration and Contact Information - Shareholders must register for the meeting by providing necessary identification and documentation, with specific instructions for both individual and corporate shareholders [6] - Contact details for the company's securities department are provided for further inquiries [6]

Core Points - The document outlines the management measures for independent directors of Chongqing Pharmaceutical Holdings Co., Ltd, aiming to enhance corporate governance and protect the interests of minority shareholders [2][20] - It specifies the qualifications, responsibilities, and operational procedures for independent directors to ensure their independence and effectiveness in decision-making [3][5] Summary by Sections General Principles - The purpose of the measures is to improve corporate governance and regulate the behavior of independent directors [2] - Independent directors must not hold any other positions within the company and should have no direct or indirect interests that could affect their judgment [2][3] - Independent directors are obligated to act in good faith and diligence, ensuring the protection of minority shareholders' rights [3] Qualifications and Appointment - Independent directors must meet specific independence criteria, including not being related to major shareholders or having significant business ties with the company [5][6] - The company must ensure that independent directors constitute at least one-third of the board, including at least one accounting professional [2][3] Responsibilities and Duties - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice [8][10] - They have the authority to independently hire external consultants for audits or consultations [8][10] Operational Procedures - Independent directors must attend board meetings and can delegate their voting rights if unable to attend [9][10] - They are required to submit annual reports detailing their attendance, participation in committees, and communication with minority shareholders [14][15] Support and Resources - The company must provide necessary support and resources for independent directors to fulfill their duties effectively [17][19] - Independent directors are entitled to reasonable compensation and may have access to liability insurance [19][20]

General Principles - The purpose of the rules is to standardize the board meeting procedures and improve the efficiency and scientific decision-making of the board [1] - The board of directors is the decision-making body for the company's management, responsible for the company's development goals and major operational activities [1][2] Board Composition and Qualifications - The board consists of 11 directors, including 4 independent directors [3] - Directors must be natural persons and cannot hold office if they meet certain disqualifying conditions, such as criminal convictions or bankruptcy responsibilities [2][3] Board Operations - Directors are elected by the shareholders for a term of three years and can be re-elected [3] - The board can increase or decrease its members based on business needs, but any changes must be approved by the shareholders [4] - Directors who fail to attend meetings without proper delegation may be recommended for replacement [4] Responsibilities and Powers of the Board - The board has the authority to convene shareholder meetings, execute resolutions, and decide on major operational plans and investment proposals [6][7] - The chairman of the board is responsible for presiding over meetings and ensuring the execution of board resolutions [22][24] Independent Directors - Independent directors must account for at least one-third of the board and include at least one accounting professional [9][10] - The nomination and election of independent directors must comply with relevant regulations and be disclosed to shareholders [10][11] Committees of the Board - The board establishes specialized committees, including the Strategy and Sustainable Development Committee, Audit and Risk Committee, Nomination Committee, and Compensation and Assessment Committee [14][15] - Each committee is responsible for specific functions and must report to the board [14][15] Board Meetings - The board must hold at least two meetings annually, with proper notice provided to all directors [19][20] - Decisions require a majority vote from attending directors, and specific procedures must be followed for related party transactions [22][23] Documentation and Compliance - Meeting minutes must be recorded and maintained for at least ten years, and decisions made must comply with legal and regulatory requirements [24][25] - The board secretary is responsible for managing documentation, coordinating meetings, and ensuring compliance with disclosure obligations [15][16]

General Provisions - The company aims to protect the legal rights of shareholders, employees, and creditors while ensuring the preservation and appreciation of state-owned assets, in accordance with relevant laws and regulations [1] - The company is established as a joint-stock limited company approved by the Chongqing Municipal Government and registered with the Chongqing Market Supervision Administration [2] - The company was approved by the China Securities Regulatory Commission for its initial public offering of 55 million shares, listed on the Shenzhen Stock Exchange [3] Company Structure - The registered capital of the company is RMB 1,728,184,696 [2] - The company is a permanent joint-stock limited company, with the chairman serving as the legal representative [2] - The legal representative's civil activities conducted on behalf of the company will have legal consequences for the company [2] Governance and Management - The company establishes a party committee in accordance with the Communist Party of China regulations, which plays a leading role in corporate governance [3] - The company implements a dual-entry and cross-appointment leadership system, allowing qualified members of the party committee to enter the board of directors and management [4] Business Objectives and Scope - The company's business objective is to provide comprehensive pharmaceutical services, ensuring the public has access to safe medications, and to achieve integrated development in the pharmaceutical industry [5] - The company is engaged in various licensed activities, including drug production, transportation, and investment in pharmaceutical research and sales projects [5] Share Issuance and Management - The company's shares are issued in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued by the company is 1,728,184,696, all of which are ordinary shares denominated in RMB [6] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in decision-making processes, including the right to propose and vote on resolutions at shareholder meetings [11][12] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not misuse their rights to harm the company or other shareholders [16] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [20] - The company must provide legal opinions on the legality of the meeting's procedures and resolutions [21] Voting and Resolutions - Resolutions at shareholder meetings can be classified as ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring a two-thirds majority [32] - The company must ensure that voting results, especially those affecting minority investors, are disclosed promptly [33]

Core Viewpoint - The establishment of the Audit and Risk Committee aims to enhance the decision-making function of the board of directors, ensuring effective supervision of the management team and improving corporate governance structure [1]. Group 1: Committee Structure - The committee consists of three directors, all of whom are external directors, including two independent directors, with an accounting professional serving as the convener [2]. - The committee members must possess the necessary professional knowledge and experience to effectively supervise and evaluate internal and external audit work [2]. Group 2: Responsibilities and Authority - The main responsibilities of the committee include supervising and evaluating external and internal audit work, reviewing financial information and disclosures, and overseeing internal controls [3]. - The committee has the authority to propose the hiring or replacement of external audit firms and to supervise the actions of directors and senior management [3][4]. Group 3: Meeting Procedures - The committee is required to meet at least once a quarter, with provisions for special meetings as needed [6][8]. - A quorum for meetings requires the presence of at least two-thirds of the committee members, and decisions must be approved by a majority [8][9]. Group 4: Reporting and Accountability - The committee must review the company's financial reports and ensure their authenticity, accuracy, and completeness, focusing on significant accounting and auditing issues [5]. - The committee is responsible for reporting any violations of laws or regulations by directors or senior management to the board or shareholders [5][6].

Core Viewpoint - The company plans to repurchase shares to reduce registered capital, with a total repurchase amount between RMB 80 million and RMB 100 million, and a maximum price of RMB 6.6 per share [1][3][4] Summary by Relevant Sections Repurchase Purpose and Amount - The repurchased shares will be used to reduce the company's registered capital [1] - The total repurchase amount is set between RMB 80 million and RMB 100 million [1][4] Funding and Price - The funding sources for the repurchase will be the company's own funds and a special loan for stock repurchase [1][4] - The maximum repurchase price is capped at RMB 6.6 per share [1][3] Expected Repurchase Quantity - The estimated number of shares to be repurchased is approximately 15,151,515 shares, accounting for about 0.88% of the current total share capital of 1,728,184,696 shares [1][4] - The estimated range for the number of shares is between 12,121,212 and 15,151,515 shares [4][5] Repurchase Method and Duration - The repurchase will be conducted through the Shenzhen Stock Exchange trading system via centralized bidding [1][3] - The duration for the repurchase is set for 12 months from the date of approval by the shareholders' meeting [1][3] Compliance and Conditions - The repurchase plan must be approved by the shareholders' meeting, and there are risks associated with not obtaining this approval [2][9] - The company has received a loan commitment from China Everbright Bank for up to RMB 90 million for the repurchase [4][6] Impact on Company Structure - Post-repurchase, the company's total share capital will decrease, with the number of circulating shares expected to be reduced accordingly [5][6] - The management believes that the repurchase will not adversely affect the company's operational, financial, or developmental capabilities [6][7] Management Commitments - The board of directors commits to maintaining the interests of all shareholders and creditors, ensuring that the repurchase does not harm the company's debt repayment ability or ongoing operations [7][8]

证券代码：000950 证券简称：重药控股 公告编号：2025-042 重药控股股份有限公司 关于回购股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.拟回购股份基本情况 （1）回购用途：本次回购的股份将用于减少公司注册资本。 （2）回购金额：不低于人民币8,000万元（含本数），不超过人民币10,000万 元（含本数）。 （3）资金来源：公司自有资金及股票回购专项贷款。 （4）回购价格：不超过人民币6.6元/股（含本数）。 （5）回购数量：按本次拟用于回购的资金总额上限及回购价格上限测算，预 计回购股份数量约为15,151,515股，约占公司当前总股本1,728,184,696股的0.88%； 按本次拟用于回购的资金总额下限及回购价格上限测算，预计回购股份数量约为 12,121,212股，约占公司当前总股本的0.70%。具体回购股份数量以回购期限届满 时实际回购的股份数量为准。 （6）回购方式：通过深圳证券交易所交易系统以集中竞价交易方式进行股份 回购。 （7）回购期限：自股东会审议通过本次回购股份方案之日起12个月内。 （ ...

重药控股股份有限公司 董事会战略与可持续发展委员会工作细则 第一章 总则 第一条 为适应重药控股股份有限公司（以下简称"公司"）战略需要，增强 公司核心竞争力，确定公司发展规划，健全投资决策程序，加强决策科学性，提 高重大投资决策的效益和决策的质量，提升公司可持续发展和环境、社会及公司 治理（以下简称"ESG"）管理水平，使董事会战略与可持续发展委员会（以下简 称"委员会"）工作规范化、制度化，根据《公司法》等法律、法规、规范性文件 及《公司章程》的相关规定，公司特设立董事会战略与可持续发展委员会，并制 定本细则。 第二条 委员会是董事会下设专门机构，对董事会负责，主要负责对公司长 期发展战略、重大投资决策和公司 ESG 治理工作进行研究并提出建议。 第二章 人员组成 第三条 委员会委员由七名董事组成。 第四条 委员会委员应由董事长、二分之一以上独立董事或全体董事的三分 之一提名，并由董事会选举产生。 第五条 委员会设一名主任委员（召集人）负责主持委员会工作并召集委员 会会议，主任委员原则上由董事长担任。 第六条 委员会任期与董事会任期相同，委员任期届满，连选可以连任。期 间如有委员不再担任公司董事职务，自动 ...